Skeletal muscle atrophy is induced by Fbxw beta via atrogene upregulation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Kyungshin | - |
dc.contributor.author | Ko, Young-Gyu | - |
dc.contributor.author | Jeong, Jaemin | - |
dc.contributor.author | Kwon, Heechung | - |
dc.date.accessioned | 2021-09-03T10:15:35Z | - |
dc.date.available | 2021-09-03T10:15:35Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-02 | - |
dc.identifier.issn | 1065-6995 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84727 | - |
dc.description.abstract | Muscle atrophy decreases skeletal muscle mass and is induced by inherited cachectic symptoms, genetic disorders, and sarcopenia. However, the molecular pathways associated with the onset of muscle atrophy are still unclear. In this study, we evaluated Fbxw7, a gene associated with the development of muscle atrophy in vitro and in vivo. Among the three Fbxw7 isoforms, ectopically overexpressed Fbxw7 induced the expression of myogenin and major atrogene markers (atrogin-1 and MuRF-1) and reduced myoblast differentiation. In addition, endogenous expression of Fbxw7 was also upregulated by dexamethasone, which mimics muscle atrophy in vitro, accompanied by induction of myogenin and atrogene expression in primary myoblasts. Functional analysis of Fbxw7 using short hairpin RNA (shRNA) and a dominant-negative mutant (Fbox) suggested that Fbxw7 regulated muscle atrophy in vitro and in vivo. In particular, Fbox did not reduce the sizes of muscle fibers and did not induce myogenin and atrogene expression in vivo. Therefore, our findings demonstrated, for the first time, that Fbxw7 induced muscle atrophic phenotypes via atrogenes in adult muscle precursor cells and myofibers; this mechanism could be a potential therapeutic target for skeletal muscle atrophy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | TUMOR-SUPPRESSOR | - |
dc.subject | CYCLIN-E | - |
dc.subject | FBW7 | - |
dc.subject | HCDC4 | - |
dc.subject | DEFINITION | - |
dc.subject | SARCOPENIA | - |
dc.subject | MUTATIONS | - |
dc.subject | MECHANISM | - |
dc.subject | ROLES | - |
dc.subject | MICE | - |
dc.title | Skeletal muscle atrophy is induced by Fbxw beta via atrogene upregulation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ko, Young-Gyu | - |
dc.identifier.doi | 10.1002/cbin.10713 | - |
dc.identifier.scopusid | 2-s2.0-85008501996 | - |
dc.identifier.wosid | 000393312200011 | - |
dc.identifier.bibliographicCitation | CELL BIOLOGY INTERNATIONAL, v.41, no.2, pp.213 - 220 | - |
dc.relation.isPartOf | CELL BIOLOGY INTERNATIONAL | - |
dc.citation.title | CELL BIOLOGY INTERNATIONAL | - |
dc.citation.volume | 41 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 213 | - |
dc.citation.endPage | 220 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | TUMOR-SUPPRESSOR | - |
dc.subject.keywordPlus | CYCLIN-E | - |
dc.subject.keywordPlus | FBW7 | - |
dc.subject.keywordPlus | HCDC4 | - |
dc.subject.keywordPlus | DEFINITION | - |
dc.subject.keywordPlus | SARCOPENIA | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | ROLES | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordAuthor | atrogenes | - |
dc.subject.keywordAuthor | dexamethasone | - |
dc.subject.keywordAuthor | Fbxw7 | - |
dc.subject.keywordAuthor | myogenin | - |
dc.subject.keywordAuthor | skeletal muscle atrophy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.